Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
parkinson save search
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CERE | $42.15 0.02% 0.02% 810K
|
Finance
|
| O: 0.78%
H: 0.0%
C: 0.0%
disease positive for topline parkinson’s trial therapeutics results living
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: -15.02%
H: 3.55%
C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
Published: 2024-04-17 (Crawled : 01:00) - alteritytherapeutics.com
ATHE | $2.04 -4.67% -4.9% 54K
|
Health Technology
|
| O: 0.0%
H: 7.32%
C: -1.95%
disease neurology system meeting parkinson’s therapeutics
IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
IGXT | $0.17 -19.77% 73K
|
Manufacturing
|
| O: -5.24%
H: 8.65%
C: 8.65%
versafilm first disease montelukast parkinson’s trial
BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS™ to Treat Parkinson's Disease
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
BWAY | $4.835 0.94% 0.93% 41K
|
Health Technology
|
| O: 6.79%
H: 0.0%
C: -7.9%
disease parkinson's review treat potential results
Indivi to Collaborate with Biogen to Advance Digital Health Technology and Digital Biomarkers for Parkinson's Disease
Published: 2024-03-26 (Crawled : 19:00) - biospace.com/
DNLI | $15.98 -3.74% -3.88% 1.5M
|
Health Technology
|
| O: 1.33%
H: 0.25%
C: -1.27%
disease parkinson's health technology biomarkers
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
Published: 2024-03-08 (Crawled : 12:00) - globenewswire.com
ATHA | $2.12 2.91% 2.83% 200K
|
Health Technology
|
| O: 0.0%
H: 1.45%
C: -13.73%
fosgonimeton pharma conference alzheimer’s international preclinical parkinson’s potential
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024
Published: 2024-03-07 (Crawled : 15:30) - globenewswire.com
VAXX | News | $0.4761 2.43% 2.37% 290K
|
|
| O: -1.42%
H: 37.63%
C: 11.15%
disease positive parkinson’s trial
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
Published: 2024-03-07 (Crawled : 13:30) - globenewswire.com
IKT | $2.1 0.19% 52K
|
Health Technology
|
| O: 0.41%
H: 2.89%
C: 0.0%
conference alzheimer’s update international disorders neurological parkinson’s trial therapeutics
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
Published: 2024-03-05 (Crawled : 13:00) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: -4.66%
H: 6.67%
C: 3.56%
gt-0228 conference disease treatment parkinson’s therapeutics
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting
Published: 2024-03-04 (Crawled : 21:00) - globenewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.62%
H: 0.84%
C: -1.1%
conference alzheimer’s international meeting parkinson’s
Kenai Emerges from Stealth With $82M Series A, Targets Parkinson’s
Published: 2024-03-01 (Crawled : 17:00) - biospace.com/
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
| Email alert
Add to watchlist
series parkinson’s
BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024
Published: 2024-03-01 (Crawled : 13:00) - globenewswire.com
BIVI | $0.4874 -0.21% -0.21% 490K
|
Health Technology
|
| O: 141.13%
H: 10.7%
C: -36.79%
ne3107 conference disease alzheimer’s international parkinson’s potential
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Published: 2024-02-27 (Crawled : 19:00) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: 0.22%
H: 3.45%
C: -3.88%
gt-0228 disease parkinson’s trial therapeutics therapy
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
Published: 2024-02-14 (Crawled : 18:00) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 5.32%
C: 4.88%
disease update parkinson’s therapeutics
UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
Published: 2024-02-06 (Crawled : 15:00) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: -0.46%
H: 7.55%
C: 2.29%
gt-0228 disease update parkinson’s
Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
Published: 2024-02-06 (Crawled : 13:00) - globenewswire.com
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: -0.46%
H: 7.55%
C: 2.29%
gt-0228 disease parkinson’s
Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement
Published: 2024-01-24 (Crawled : 13:00) - globenewswire.com
ANVS | $10.09 2.44% -0.15% 220K
|
Health Technology
|
| O: -10.18%
H: 0.0%
C: -13.06%
announcement parkinson’s study
CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics
Published: 2024-01-23 (Crawled : 12:00) - globenewswire.com
CNTG | $0.463 0.43% 0.43% 79K
|
Commercial Services
|
| O: 0.0%
H: 0.0%
C: 0.0%
disease genetic risk research parkinson’s
AbbVie Launches PRODUODOPA® (foslevodopa/foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union
Published: 2024-01-09 (Crawled : 07:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.56%
H: 1.26%
C: 0.55%
produodopa disease abbvie parkinson's advanced living
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.